J Clin Oncol 28111850-1855. doiAlexandrov LB Nik-Zainal S Wedge DC Aparicio SA Behjati S Biankin AV Bignell GR Bolli N Borg A Borresen-Dale AL Boyault S Burkhardt B Butler AP Caldas C Davies HR Desmedt C Eils R Eyfjord JE Foekens JA Greaves M Hosoda F Hutter B Ilicic T Imbeaud S Imielinski M Jager N Jones DT Jones D Knappskog S Kool M Lakhani SR Lopez-Otin C Martin S Munshi NC Nakamura H Northcott PA Pajic M Papaemmanuil E Paradiso A Pearson JV Puente XS Raine K Ramakrishna M Richardson AL Richter J Rosenstiel P Schle- sner M Schumacher TN Span PN Teague JW Totoki Y Tutt AN Valdes-Mas R van Buuren MM van 't Veer L Vincent- Salomon A Waddell N Yates LR Australian Pancreatic Can- cer Genome I Consortium IBC Consortium IM-S PedBrain I Zucman-Rossi J Futreal PA McDermott U Lichter P Mey- erson M Grimmond SM Siebert R Campo E Shibata T Pfis- ter SM Campbell PJ Stratton MR 2013 Signatures of muta- tional processes in human cancer.

Science 35062641084-1089. doiVetizou M Pitt JM Daillere R Lepage P Waldschmitt N Fla- ment C Rusakiewicz S Routy B Roberti MP Duong CP Poir- ier-Colame V Roux A Becharef S Formenti S Golden E Cord- ing S Eberl G Schlitzer A Ginhoux F Mani S Yamazaki T Jacquelot N Enot DP Berard M Nigou J Opolon P Eggermont A Woerther PL Chachaty E Chaput N Robert C Mateus C Kroemer G Raoult D Boneca IG Carbonnel F Chamaillard M Zitvogel L 2015 Anticancer immunotherapy by CTLA-4 block- ade relies on the gut microbiota.

Can- cer Discov 68827-837. doiPeng W Chen JQ Liu C Malu S Creasy C Tetzlaff MT Xu C McKenzie JA Zhang C Liang X Williams LJ Deng W Chen G Mbofung R Lazar AJ Torres-Cabala CA Cooper ZA Chen PL Tieu TN Spranger S Yu X Bernatchez C For- get MA Haymaker C Amaria R McQuade JL Glitza IC Cas- cone T Li HS Kwong LN Heffernan TP Hu J Bassett RL Jr. Bosenberg MW Woodman SE Overwijk WW Lizee G Roszik J Gajewski TF Wargo JA Gershenwald JE Radvanyi L Davies MA Hwu P 2016 Loss of PTEN promotes resistance to T cell-mediated immunotherapy.

J Clin Oncol 32101020-1030. doiRobert C Long GV Brady B Dutriaux C Maio M Mortier L Hassel JC Rutkowski P McNeil C Kalinka-Warzocha E Savage KJ Hernberg MM Lebbe C Charles J Mihalcioiu C Chiarion- Sileni V Mauch C Cognetti F Arance A Schmidt H Schaden- dorf D Gogas H Lundgren-Eriksson L Horak C Sharkey B Waxman IM Atkinson V Ascierto PA 2015 Nivolumab in pre- viously untreated melanoma without BRAF mutation.

J Clin Oncol vol 34 suppl abstr 9518Hodi FS KH Sznol M Carvajal R Lawrence D Atkins M Pow- derly J Sharfman W Puzanov I Smith D Leming P Lipson E Taube J Anders R Horak C Jiang J McDermott D Sosman J Brahmer J Pardoll D Topalian S 2016 Durable long-term survival in previously treated patients with advanced melanoma MEL who received nivolumab NIVO monotherapy in a phase I trial In 107th Annual Meeting of the American Association for Cancer Research New Orleans LA April 16-20 2016Robert C RA Hamid O Daud A Wolchok JD Joshua AM Hwu W-J Weber JS Gangadhar TC Joseph RJ Dronca RS Patnaik A Zarour HM Kefford R Hersey P Li X Diede SJ Ebbing- haus S Hodi FS 2016 Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEY- NOTE-001.

Lancet Oncol 168908-918. doiRobert C Schachter J Long GV Arance A Grob JJ Mortier L Daud A Carlino MS McNeil C Lotem M Larkin J Lorigan P Neyns B Blank CU Hamid O Mateus C Shapira-Frommer R Kosh M Zhou H Ibrahim N Ebbinghaus S Ribas A investiga- tors K- 2015 Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Lancet 387100311909-1920. doiDreicer R Hoffman-Censits J Flaig T Grande E Balmanouk- ian A von Amsberg G Theodore C Chowdhury S Bracarda S Clement JM Yu E Kalebasty AR Niegisch G Culine S GM Ding B Mariathasan S Legrand F Abidoye OO DP P Updated efficacy from IMvigor210 Atezolizumab in platinum-treated locally advancedmetastatic urothelial carcinoma mUC.

Cancer Immunol Immunother 657797- 804. doiKamata T Suzuki A Mise N Ihara F Takami M Makita Y Horinaka A Harada K Kunii N Yoshida S Yoshino I Nakayama T Motohashi S 2016 Blockade of programmed death-1programmed death ligand pathway enhances the anti- tumor immunity of human invariant natural killer T cells.

N Engl J Med 373171627-1639. doiBrahmer J Reckamp KL Baas P Crino L Eberhardt WE Poddubskaya E Antonia S Pluzanski A Vokes EE Holgado E Waterhouse D Ready N Gainor J Aren Frontera O Havel L Steins M Garassino MC Aerts JG Domine M Paz-Ares L Reck M Baudelet C Harbison CT Lestini B Spigel DR 2015 Nivolumab versus docetaxel in advanced squamous- cell non-small-cell lung cancer.

Ann Oncol 27149-61. doiGalsky MD Retz M Siefker-Radtke A Baron A Necchi A Bedke J Plimack ER Vaena D Grimm MO Bracarda S Angel Arranz J Pal S Ohyama C Saci A Lambert A Krishnan S Azrilevich A Sharma P 2016 Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer mUC who have received prior treatment results from the phase IICheckMate 275 study.

